X

Global Peptide Receptor Radionuclide Therapy Market to Register a CAGR of 12.4% during the Forecast Period

The global peptide receptor radionuclide therapy (PRRT) market size is anticipated to grow at a CAGR of 12.4% during the forecast period. Targeted radionuclide therapy is known to be peptide receptor radionuclide therapy (PRRT) since it provides radiation through radiolabelled peptides to kill cancer cells. There are three types of radiation used in the peptide receptor radionuclide procedure, which are β-particles (electrons), alpha particles, and Auger electrons.

In PRRT, β-particles (electrons) are commonly used since it has a long range to penetrate the targeted cells/tissues (0.05-12 mm) and neighboring cells. Peptide receptor radionuclide therapy (PRRT) is used mainly in the treatment of neuroendocrine tumors of the pancreatic and gastrointestinal tract.

PRRT is a molecular therapy, also called radioisotope therapy. This method of therapy is used for the treatment of neuroendocrine tumors, a particular type of cancer. A targeting protein or peptide is mixed with a small amount of radioactive material during peptide receptor radionuclide therapy and inserted into the bloodstream of patients. This radio peptide travels to the neuroendocrine tumor cells and then binds with them, to give a targeted high dose of radiation directly to the cancer cells.

During the forecast period, the global demand for peptide receptor radionuclide therapy (PRRT) is expected to grow significantly due to an increase in the incidence of gastro-entero-pancreatic neuroendocrine tumors. One of the significant factors that is expected to drive the demand is increased understanding about the successful use of peptide receptor radionuclide therapy.

More personalized cancer care can be provided through peptide receptor radionuclide therapy, as radio peptides are highly selective in their ability to directly enter and destroy neuroendocrine tumor cells, thus reducing exposure to radiation. This has boosted the global market for peptide receptor radionuclide therapy.

The economic effect of cancer is rising dramatically, according to the World Health Organization's 2018 data. The gross annual economic cost of care for cancer was estimated at US$ 1.16 trillion worldwide in 2010. In addition, until 2018, only one PRRT drug based on peptide receptor radionuclide therapy (PRRT) was approved in the U.S. and Europe, and was used in the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including neuroendocrine tumors of the foregut, midgut, and hindgut.

Market growth over the forecast period is projected to be powered by an increased occurrence of pancreatic neuroendocrine and gastrointestinal tract neuroendocrine tumors. According to 2019 figures from the American Society of Clinical Oncology (ASCO), about 1,000 individuals in the U.S. are diagnosed with pancreatic neuroendocrine tumor each year, and it accounts for 7 percent of cases of pancreatic cancer. In the US, the number of patients diagnosed with pancreatic neuroendocrine tumor has risen by around 5 percent per year, according to the same source.

The growth of the global peptide receptor radionuclide treatment (PRRT) market over the forecast period is expected to be guided by growing pipeline studies to develop novel radio peptide therapy. For example, in May 2018, Merck Sharp & Dome Corp launched a Type II clinical trial on peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive metastases, in collaboration with BTG International Inc. By November 2020, the analysis was scheduled to be completed.

Peptide radionuclide receptor therapy (PRRT) is technologically advanced and is specifically designed to improve health outcomes at any level. The realistic implementation of these innovations in the real world can improve the health of patients and drive positive results for the population as a whole. The market for PRRT is growing owing to the rising investment by manufacturers in radiopharmaceuticals for cancer treatment and increased government investment in cancer therapy and drug development.

Global Peptide Receptor Radionuclide Therapy Market, By Disease Indication

Based on disease indication, the market has been segmented into pancreatic – neuroendocrine tumor, gastrointestinal tract - neuroendocrine tumor, and others. As per the current market scenario, the largest peptide receptor radionuclide therapy (PRRT) market share has been captured by the pancreatic - neuroendocrine tumor segment. This segment is also expected to have a higher CAGR during the forecast period. The pancreatic -neuroendocrine tumor has low toxicity and immunogenicity, minimizing the risk of tumor therapy in patients with infections and allergies.

Global Peptide Receptor Radionuclide Therapy Market, By End-user

On the basis of end-users, the global market has been segmented into hospitals, ambulatory surgical centers, and cancer care centers. Among these, the hospital segment accounted for the largest share of the market for peptide receptor radionuclide therapy (PRRT) in 2018. It is further anticipated that rising demand for multi-specialty care and equipment and increasing patient preference for technologically advanced surgical procedures performed in hospitals would increase the segment’s growth over the forecast period.

Global Peptide Receptor Radionuclide Therapy Market, By Geographical Regions

North America has a leading position in the global market for peptide receptor radionuclide therapy (PRRT) in terms of sales. The dominance of the region can be attributed to favorable government policies for disease prevention and adoption of HCIT, increased funding for peptide receptor radionuclide therapy (PRRT), increased prevalence of chronic diseases, and the existence of a well-developed healthcare infrastructure in the region.

Key Market Developments:

  • Novartis AG obtained approval from the European Commission in November 2018 for luxturna, a gene therapy for the treatment of patients with vision loss. The approval strengthens the company's brand identity and increases its consumer base.
  • Novartis AG signed a partnership agreement with Caribou in January 2017. Innovation and development of gene therapy are the priority of the collaboration.

Some Key Findings of the Global Peptide Receptor Radionuclide Therapy Market Report are:

  • A comprehensive analysis of the parent market.
  • Year-on-year growth of the global peptide receptor radionuclide therapy market in terms of value and volume.
  • Historic and future progress of the global market.
  • Region-wise and country-wise analysis of the global peptide receptor radionuclide therapy market to get the share and growth details in these areas.
  • The key factors that are impacting the consumption pattern of consumers across regions and countries.
  • Strategic framework of the global peptide receptor radionuclide therapy market to boost the growth journey
  • Crucial insights regarding the current R&D activities performed by each market service provider.
  • Some of the key players in the global market are Novartis, Australasian Gastro-Intestinal Trials Group, Sarepta Therapeutics, Caribou, Finvector, Sangamo Therapists Inc., ITM Solucin, Allscripts Healthcare Solutions, Inc., Sirion Biotech, and bluebird bio.

Market Segmentation:

By Disease Indication

  • Pancreatic - Neuroendocrine Tumor
  • Gastrointestinal Tract - Neuroendocrine Tumor
  • Others

By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Cancer Care Centers

By Region:

  • North America
  • Western Europe
  • Eastern Europe
  • Asia Pacific
  • Middle East
  • Rest of the World
Detailed Coverage

Detailed scope covering all the major segments in the market

Meticulous Data Validations

In line data validations to ensure data precision

Recommendations

Market recommendations supporting decision making processes

Analyst Support

Round the clock analyst support to resolve your queries

Free Customization

Up to 15% additional free customization to meet your specific requirements